Recombinant equine
FSH has been shown to induce development of numerous pre-ovulatory follicles in
the ovary of the mare. An increase in the number of pre-ovulatory follicles
increases the chances of pregnancy or the number of embryos for embryo transfer
after the mare is bred. Recombinant equine FSH was
developed as a single chain gonadotropin that conveys to the hormone multiple
benefits such as increased stability and efficiency as well as ease of
production in the laboratory. Briefly, the treatment
protocol involves intramuscular (IM) injections 1-2 times per day over a 5-7
day period starting approximately 4 days post-ovulation in cycling mares. A
similar protocol is used for anestrous mares without artificial lights starting
at any time early February in the non-breeding season. A detailed protocol is
included in the package.
|
 |
Benefits:
- Enhances the number of
pre-ovulatory follicles which results in multiple ovulations in mares for
embryo transfer thus assuring at least 2 embryos per recovery.
- Induces ovulation in the
non-breeding season without artificial lights so foals can be born earlier the
following year.
- Mares with conception
problems.
- For advanced reproductive
technology techniques such as ovum pickup and intra-cytoplasmic sperm injection
(ICIS).
- Produces follicles in mares
that had surgery to remove a granulosa cell tumor.
- Induces follicular
development in mares with seasonal or lactational anestrus.
|
 |
In summary, Fertilplus
recombinant equine FSH will reduce the cost and labor related to breeding mares
by increasing the number of embryos to transfer, decreasing conception problems
and lengthening the time of the breeding season. It also has the potential for
increasing the number of oocytes for ICIS. Research in the area of ICIS is
planned for the future. |
|
